2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy

The “2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy” provides recommendations to guide clinicians in the management of patients with hypertrophic cardiomyopathy. A comprehensive literature search was conducted from September 14, 2022, to November 22, 20...

Full description

Saved in:
Bibliographic Details
Published inJournal of the American College of Cardiology Vol. 83; no. 23; pp. 2324 - 2405
Main Authors Ommen, Steve R., Ho, Carolyn Y., Asif, Irfan M., Balaji, Seshadri, Burke, Michael A., Day, Sharlene M., Dearani, Joseph A., Epps, Kelly C., Evanovich, Lauren, Ferrari, Victor A., Joglar, José A., Khan, Sadiya S., Kim, Jeffrey J., Kittleson, Michelle M., Krittanawong, Chayakrit, Martinez, Matthew W., Mital, Seema, Naidu, Srihari S., Saberi, Sara, Semsarian, Christopher, Times, Sabrina, Waldman, Cynthia Burstein
Format Journal Article
LanguageEnglish
Published Elsevier Inc 11.06.2024
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The “2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy” provides recommendations to guide clinicians in the management of patients with hypertrophic cardiomyopathy. A comprehensive literature search was conducted from September 14, 2022, to November 22, 2022, encompassing studies, reviews, and other evidence on human subjects that were published in English from PubMed, EMBASE, the Cochrane Library, the Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline. Additional relevant studies, published through May 23, 2023, during the guideline writing process, were also considered by the writing committee and added to the evidence tables, where appropriate. Hypertrophic cardiomyopathy remains a common genetic heart disease reported in populations globally. Recommendations from the “2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy” have been updated with new evidence to guide clinicians.
ISSN:0735-1097
DOI:10.1016/j.jacc.2024.02.014